Clinico-biological Characterization and Survival of Patients With Adult T-cell Leukemia / Lymphoma...
Lymphoproliferation Induced by HTLV-1HTLV-1 Adult T-cell Lymphoma / Leukemia1 moreThe purpose of this study is to evaluate the outcome (survival) of Adult T-cell leukemia / lymphoma (ATL) patients who receive or not specific treatment for their hemopathy (cohort 1) and the outcome (survival) of HTLV-1 chronically infected patients with / without extra-haematological disorders (cohort 2).
CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
T-cell Non-Hodgkin's LymphomaThe safety and preliminary effectiveness of CD147-CAR T cells in patients with relapsed or refractory T cell non-Hodgkin's lymphoma will be investigated in this pioneering study.
Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL
Primary Extranodal LymphomaDLBCLTo assess the efficacy and safety of camrelizumab combined with rituximab, vincristine, doxorubicin, cyclophosphamide and prednisone in the treatment of untreated primary extranodal DLBCL
A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma
Hodgkin LymphomaThe main aim is to check how effective BV is for treating adults with HL. Study medication will be prescribed according to the clinic's standard practice. Participants will visit the study clinic 5 times, once every 12 weeks. When study treatment has completed, a follow-up visit will be scheduled every 3 months during the first year and every 4-6 months during the next year.
PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors
LymphomaNon-Hodgkin's1 moreProspective, multicenter, phase IV study, of real-life evidence destined to evaluate the feasibility and efficacy of performing a treatment adapted to PET-CT in patients with stage I and II DLBCL, without poor prognostic factors.
Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary CNS Lymphoma.
Primary Central Nervous System Lymphoma (PCNSL)To evaluate the safety and tolerability and determine the recommended phase 2/phase 3 dose of RAD regimen in PCNSL
Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL)
Lymphoma NonhodgkinTo ascertain the safety of Revlimid® Capsules 2.5 mg or 5 mg under the actual use conditions in patients who received R2 combination therapy with the drug and rituximab for the first time for relapsed or refractory follicular lymphoma (FL) or marginal zone lymphoma (MZL). In particular, this surveillance will collect only information of occurrence state and treatment methods on bone marrow depression (neutropenia), which is specified as a safety specification, as well as on tumor flare, for which attention should be called. Planned registration period 1.5 years Planned surveillance period 3 years from the start of this survey
CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia...
Relapsed and/or Refractory Acute Lymphoblastic LeukemiaRelapsed and/or Refractory B-cell Non-Hodgkin's LymphomaA study of CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
Lenalidomide and Low-dose Cyclophosphamide for MALT Lymphoma
Antibiotics-unresponsive MALT LymphomaRelapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma1 moreConsidering that lenalidomide and cyclophosphamide are found to have anti-tumor effects in MALT lymphoma, the investigators speculated that combined lenalidomide and low-dose cyclophosphamide can increase the overall response rate as well as dural time of tumor remission, and avoid alternative treatments, including radiotherapy or chemotherapy-related adverse effects in antibiotics-unresponsive, relapsed or refractory extranodal MALT lymphoma. Therefore, in this proposal, the investigators will design a prospective phase II study to evaluate the treatment efficacies of combination of oral lenalidomide and low-dose cyclophosphamide (LC: lenalidomide [Leavdo®] 15 mg daily, day 1 to day 21; cyclophosphamide [Endoxan] 50 mg daily, day 1 to day 21; courses will be repeated every 28 days) in patients with antibiotics-unresponsive, relapsed or refractory extranodal MALT lymphoma.
The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Mature B Cell Non-Hodgkins Lymphoma...
Non-hodgkin LymphomaThe next-generation sequencing (NGS) based on liquid biopsy has been an emerging technology to identify tumor-specific genetic aberrations in malignant tumors. The tumor tissue (FFPE) and plasma samples from the newly diagnosed pediatric mature B-NHL patients were collected and sequenced by 475 genes panel before, during and post treatment, to evaluate the significance of the ctDNA in efficacy prediction, predicting recurrence or mechanism of resistance to chemotherapy for pediatric mature B-NHL.